Shannon Campbell
Fortuna: 19 680 $ al 31/05/2026
Fortuna: 19 680 $ al 31/05/2026
Shannon Campbell is currently Director at Zentalis Pharmaceuticals, Inc. since 2026 and Independent Director at Black Diamond Therapeutics, Inc. since 2024.
Formerly, Ms. Campbell was Chief Commercial Officer & Executive VP at Merus NV from 2022 to 2026 and Vice President & General Manager-Oncology at Bayer HealthCare Pharmaceuticals, Inc. from 2005 to 2017.
Education includes undergraduate studies at Ithaca College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 27/04/2026 | 8.865 ( 0,02 % ) | 19 680 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Director/Miembro de la Junta | 10/04/2024 |
| ZENTALIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 22/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| MERUS N.V. | Corporate Officer/Principal | 01/01/2026 |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Corporate Officer/Principal | 01/01/2017 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Ithaca College
Ithaca College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical drugs | Health Technology |
Merus NV
Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.